WELCOME TO The Biotechnology REPORT
Previvo Genetics, Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
HealthMyne | September 22, 2021
HealthMyne, a pioneer in applied radiomics, announced that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy.
In the Cancers article, researchers led by Vincenza Granata evaluated HealthMyne's technology as a quantitative imaging decision support tool for radiomic analysis of lung adenocarcinoma i...
Medical, Industry Outlook
PRNewswire | June 28, 2023
QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...
PharmaCyte Biotech | September 02, 2020
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for a planned Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC). PharmaCyte’s Chief Executive Officer, Kenneth L...
FierceBiotech | February 07, 2020
After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 p...
Cell and Gene Therapy, Medical
MedTech, Industrial Impact
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE